These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 12823782)

  • 1. Alemtuzumab in lymphoproliferate disorders.
    Dearden CE
    Rev Clin Exp Hematol; 2002 Dec; 6(4):435-48; discussion 449-50. PubMed ID: 12823782
    [No Abstract]   [Full Text] [Related]  

  • 2. Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma.
    Amengual JE; Raphael BG
    Leuk Lymphoma; 2010 Jul; 51(7):1347-50. PubMed ID: 20572801
    [No Abstract]   [Full Text] [Related]  

  • 3. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
    Thursky KA; Worth LJ; Seymour JF; Miles Prince H; Slavin MA
    Br J Haematol; 2006 Jan; 132(1):3-12. PubMed ID: 16371014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful use of alemtuzumab in a child with refractory peripheral T-cell posttransplant lymphoproliferative disorder.
    Bartakke S; Abla O; Weitzman S
    J Pediatr Hematol Oncol; 2008 Oct; 30(10):787-8. PubMed ID: 19011483
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
    Lee D
    Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
    Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
    Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Campath-1H for chronic lymphocytic leukemia.
    Rai KR
    Clin Lymphoma; 2002 Sep; 3(2):73-4. PubMed ID: 12435278
    [No Abstract]   [Full Text] [Related]  

  • 8. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection.
    Woodside KJ; Lick SD
    J Heart Lung Transplant; 2007 Jul; 26(7):750-2. PubMed ID: 17613409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment.
    Monjanel H; Hourioux C; Arbion F; Colombat P; Lissandre S; Regner MP; Senecal D
    Leuk Res; 2010 Aug; 34(8):e197-9. PubMed ID: 20211489
    [No Abstract]   [Full Text] [Related]  

  • 10. Alemtuzumab for treatment of lymphoproliferative disorders.
    Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389
    [No Abstract]   [Full Text] [Related]  

  • 11. High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients.
    Au WY; Leung AY; Tse EW; Cheung WW; Shek TW; Kwong YL
    Leuk Res; 2008 Apr; 32(4):547-51. PubMed ID: 17714782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alemtuzumab in T-cell lymphoproliferative disorders.
    Dearden CE; Matutes E
    Best Pract Res Clin Haematol; 2006; 19(4):795-810. PubMed ID: 16997184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the use of alemtuzumab in CLL.
    Stilgenbauer S
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):23-4. PubMed ID: 18322437
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Zent CS
    Leuk Lymphoma; 2008 Feb; 49(2):175-6. PubMed ID: 18231900
    [No Abstract]   [Full Text] [Related]  

  • 15. Alemtuzumab, the first monoclonal antibody (MAb) directed against CD52.
    Keating M; Hallek M
    Med Oncol; 2002; 19 Suppl():S1-2. PubMed ID: 12180486
    [No Abstract]   [Full Text] [Related]  

  • 16. Buzz around Campath proof-of-concept trial in MS.
    Osborne R
    Nat Biotechnol; 2009 Jan; 27(1):6-8. PubMed ID: 19131976
    [No Abstract]   [Full Text] [Related]  

  • 17. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?
    Smith JA
    Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313
    [No Abstract]   [Full Text] [Related]  

  • 18. Alemtuzumab.
    Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
    [No Abstract]   [Full Text] [Related]  

  • 19. Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.
    Cooles FA; Jackson GH; Menon G; Isaacs JD
    Rheumatology (Oxford); 2011 Apr; 50(4):810-2. PubMed ID: 21208978
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia.
    Rosenblum MD; LaBelle JL; Chang CC; Margolis DA; Schauer DW; Vesole DH
    Blood; 2004 Mar; 103(5):1969-71. PubMed ID: 14976065
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.